A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Fulvestrant (Primary) ; Palbociclib (Primary) ; Ribociclib (Primary) ; RLY-2608 (Primary)
- Indications Advanced breast cancer; Carcinoma; Cervical cancer; Head and neck cancer; HER2 negative breast cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms ReDiscover
- Sponsors Relay Therapeutics
- 05 Jun 2024 According to a Relay Therapeutics media release, today announced a clinical trial collaboration with Pfizer Inc, to evaluate atirmociclib, in combination with RLY-2608 and fulvestrant in patients with PI3K alpha-mutated, HR+, HER2- metastatic breast cancer.
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2024 Planned End Date changed from 31 Aug 2025 to 31 Aug 2026.